We are delighted to announce the launch of the Phase 1 study of #KIT2014 for cystic fibrosis! This milestone represents an important step in our clinical development and for the cystic fibrosis community. KIT2014 targets three major unmet needs of cystic fibrosis: bronchoconstriction, mucus obstruction and inflammation. We are eager to see the results and demonstrate its strong potential to improve patient outcomes. #KIT2014 #biotech
Kither Biotech
Fabbricazione di prodotti farmaceutici
Turin, Piedmont 1.636 follower
Improving treatment for patients suffering from incurable respiratory diseases
Chi siamo
Kither Biotech is a biopharmaceutical company that develops novel therapies for the treatment of rare pulmonary diseases with an high unmet medical need. Our first two product candidates KIT2014 and KITCL27, focus on cystic fibrosis and idiopathic pulmonary fibrosis respectively.
- Sito Web
-
https://kitherbiotech.com
Link esterno per Kither Biotech
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 2-10 dipendenti
- Sede principale
- Turin, Piedmont
- Tipo
- Società privata non quotata
Località
-
Principale
Ottieni indicazioni
Via Nizza, 52
Turin, Piedmont 10126, IT
Dipendenti presso Kither Biotech
-
Marco Kevin Malisani
Co-founder and Executive Director at Kither Biotech
-
Kishor Lad
Life Science Data Management Consultant
-
Valentina Sala
Drug Development Specialist, Kither Biotech
-
Giovanni Longhi
CFO | Business Advisor | Business Angel | Startup Mentor | Business Strategist | Simest Financing Specialist
Aggiornamenti
-
Kither Biotech is thrilled to be attending BIO-Europe! We're looking forward to sharing the latest advancements of #KIT2014, our asset in cystic fibrosis, and exploring opportunities for future partnerships. Connect with our CEO, Dimitrios Goundis, and Head of Scientific Affairs, Valentina Sala, to learn more about our respiratory portfolio. #BIOEurope #Biotech #Innovation #KIT2014 #CysticFibrosis
-
-
We are thrilled to announce that our company has been recognized as one of the top biotech companies in Italy by Labiotech.eu This achievement is a reflection of the relentless dedication and hard work of our entire team! We remain steadfast in our commitment to pioneering innovations in the fight against cystic fibrosis and idiopathic pulmonary fibrosis. #KIT2014 #KITCL27 #biotech
-
We're thrilled that our Director, Pietro Puglisi, is taking part in the J.P. Morgan Healthcare Conference in San Francisco! This is a great opportunity to connect with him and learn more about the groundbreaking work we're doing at Kither Biotech! #biotech #jpm2024 #KIT2014
-
Pagine simili
Raccolta fondi
Kither Biotech
2 round in totale
Vedi altre informazioni su Crunchbase
Ultimo round
Serie B
Link al sito Crunchbase esterno per l’ultimo round di raccolta fondi
20.390.124,00 USD